UK's MHRA brings in stem cell robot to help develop therapies

4 April 2024

A new robot that grows stem cells is being trialled by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Potentially able to bring safer and more cost-effective treatments to people with a wide range of diseases, the CellQualia Intelligent Cell Processing System is the only one in the world outside of Japan, where it was developed.

The trial is part of a UK-based international research program, launched in 2021, and a partnership between the MHRA, Scottish regenerative medicine start-up Sakarta and Tokyo-based electrical equipment manufacturer Sinfonia Technology, with support from the Foundation for Biomedical Research and Innovation at Kobe.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK